The UK and US have reached a significant trade agreement that will preserve no levies on British medicine exports entering the US market.
Key Provisions of the Pact
In exchange for the tariff guarantee, the UK has pledged to increase expenditure on medicines through the National Health Service (NHS). This pledge secures that tariffs on these key products will be held at nothing for a timeframe of the next three years.
This development comes after recent warnings to dramatically increase tariffs on branded drug products, with potential rates mentioned up to double the cost.
"This arrangement between the United Kingdom strengthens the worldwide climate for innovative medicines and brings much-needed equity to transatlantic pharmaceutical trade," a release declared.
Trade Importance
Drugs are one of the Britain's biggest export categories to the United States, which is by far the biggest destination for leading companies like GSK and AstraZeneca.
Statistics indicate that in the one-year period prior to last September, the UK sold drugs worth over eleven billion pounds to the US. This value represented a significant portion of total UK exports in that timeframe.
"This deal protects jobs, stimulates investment and paves the way for the UK to emerge as a worldwide center for biotech and pharma," a minister commented.
Key NHS Changes
The agreement involves several specific pledges from the UK:
- Revised Affordability Limit: The UK will raise the cost ceiling at which it deems new treatments to be unaffordable by a quarter.
- Increased NHS Spending: There is a target to double overall public funding on treatments from 0.3% of GDP to 0.6% over the next decade.
- Refund Ceiling: The percentage drug companies must return to the NHS to control costs will be restricted at 15%. In the past, refunds were more than twenty percent.
Recent Tensions
The pact takes place against a ongoing dispute between the drug companies and the UK government over drug pricing and NHS adoption.
The disagreement were heightened by assertions that US patients were charged significantly more for the identical medicines than patients in the Britain and the EU.
In recent months, several large drug company projects in the UK have been delayed or abandoned, while major expansions have been pledged toward US facilities.
The Science Minister stated that the NHS must spend more on treatments, noting that its spending on drugs had shrunk as a proportion of its overall budget over the previous ten-year period.
